Incidence Evaluation of Acute Kidney Injury and Pharmacoeconomic Analysis Among Critically Ill Patients With Use of Antipseudomonal β-Lactams and Vancomycin

Yalin Dong, Ying Zhang, Yan Wang, Jiangping Lian, Ruixia Yang, Lihui Long, Yin Wu, Yan Jianhua, Fei Shang, Kanghuai Zhang, Lirong Peng, Jianlin Huang, Dong Liu, Xialing Jiao, Linghong Huang, Kangkang Yan, Xiaoe Li, Hefeng Zhang, Yaling Shi, Bao Sun, Wenli Hai, Xiaoting Li, Jianping Zhang, Yan Cai, Xiaonian Han, Wangwang Duan, Jin Zhang, Kai Jiang, Le Zhang, Minchun Chen, Yan-Sheng KangResearch Square 2021 · DOI

Abstract

Background: Whether vancomycin (VAN) plus piperacillin-tazobactam (PTZ) could increase the risk of acute kidney injury (AKI) is still controversial in critically ill patients. The purpose of this study was to compare the risk of developing AKI and treatment cost among this population receiving VAN/PTZ to a matched group receiving VAN/other antipseudomonal β-lactams. Methods: This multicenter, retrospective, matched study included 700 critically ill patients who received ≥48 hours of VAN/PTZ or VAN/other antipseudomonal β-lactams. The risk of developing AKI was compared between these two combination therapies using propensity-adjusted analysis. Furthermore, a pharmacoeconomic decision-analytic model was performed. Results: According to three AKI-defined criteria, VAN/PTZ was associated with significantly higher incidence than VAN/other antipseudomonal β-lactams (all P < 0.001). In multivariate analysis, regardless of any VAN/other antipseudomonal β-lactams, VAN/PTZ was an independent predictor for stage 2 or 3 AKI. In the empiric treatment, the incremental cost-effectiveness ratios per additional nephrotoxic episode of $1147.35, $1845.11, and $3989.95 were found for VAN/PTZ relative to vancomycin plus imipenem-cilastatin, vancomycin plus meropenem, and vancomycin plus cefoperazone-sulbactam, respectively. Conclusion: In critically ill patients, VAN/PTZ was associated with both higher AKI risk and treatment cost when considering AKI occurrence compared to VAN/other antipseudomonal β-lactams.

Introduction

In the management of critically ill patients, particularly those facing sepsis or severe hospital-acquired infections, clinicians frequently employ "broad-spectrum" antibiotic regimens. A common standard of care is the combination of Vancomycin (VAN) with an antipseudomonal β-lactam, most often Piperacillin-Tazobactam (PTZ).

However, emerging evidence suggests that the VAN/PTZ combination may significantly increase the risk of Acute Kidney Injury (AKI) compared to other β-lactam pairings. While this association has been observed in general hospital settings, data specifically for critically ill patients—who are already predisposed to organ dysfunction—has remained inconsistent. This study aims to clarify both the clinical risk and the economic implications of choosing VAN/PTZ over alternative antipseudomonal combinations in the ICU.

Methods

This research utilized a multicenter, retrospective, matched cohort design, analyzing data from 1,559 patients across 16 medical centers in China between 2008 and 2018. The final analysis focused on a matched cohort of 700 critically ill adults: 154 in the VAN/PTZ group and 546 in the VAN/Other group (including combinations with Meropenem, Cefoperazone-sulbactam, or Imipenem-cilastatin).

To address potential selection bias inherent in retrospective data, the researchers employed propensity-score matching. This technique balanced the cohorts based on baseline characteristics such as age, weight, severity of illness scores (APACHE II and SOFA), and various comorbidities.

Baseline characteristics (Part 1) of unmatched and matched patient cohorts.
Baseline characteristics (Part 2) including comorbidities and clinical status.

Additionally, a pharmacoeconomic decision-analytic model was constructed using TreeAge Pro software. The primary economic metric was the Incremental Cost-Effectiveness Ratio (ICER), which calculated the cost required to prevent one additional episode of nephrotoxicity when selecting alternative therapies over VAN/PTZ.

Results

Clinical Outcomes

The study found a stark difference in AKI incidence. Patients receiving VAN/PTZ experienced a 29.1% incidence of AKI, compared to 12.5% in the group receiving other β-lactams (P < 0.001). Furthermore, VAN/PTZ was specifically associated with a higher rate of severe AKI (Stage 2 or 3), occurring in 18.2% of patients versus 5.6% in the comparison group. Multivariate analysis confirmed that VAN/PTZ is an independent predictor for severe AKI, even after adjusting for factors like sepsis and vasopressor use.

Economic Impact

Beyond clinical safety, the choice of antibiotic had significant financial consequences. While PTZ is a common and relatively inexpensive drug, the costs associated with the AKI it may induce—such as extended ICU stays (averaging 20 days vs. 18 days)—make it less cost-effective in the long run. The pharmacoeconomic analysis revealed that VAN/PTZ was "dominated" by other therapies. For instance, opting for Vancomycin plus Cefoperazone-sulbactam instead of VAN/PTZ could save approximately $3,989.95 for every nephrotoxic episode prevented.

Discussion and Conclusion

The findings suggest that the VAN/PTZ combination acts as a "double whammy" for the kidneys in critically ill populations. The study noted that drug-induced AKI typically manifests within 4 to 8 days of therapy, highlighting a critical window for antibiotic stewardship. If clinicians can de-escalate or transition to safer antibiotic combinations within the first 72 hours, they may significantly reduce the risk of kidney damage.

Limitations

The study's retrospective nature means it identifies correlations rather than definitive causation. Additionally, the use of Serum Creatinine as a proxy for AKI may lag behind actual injury. Future research incorporating more sensitive biomarkers and accounting for vancomycin trough levels is warranted to further elucidate the biological mechanisms behind PTZ-exacerbated toxicity.

In conclusion, for critically ill patients, the use of VAN/PTZ is associated with both a higher risk of AKI and increased overall treatment costs. Clinicians should consider alternative antipseudomonal β-lactams to improve patient safety and healthcare efficiency.

Summary updated

Abstract

<title>Abstract</title> <bold>Background</bold>: Whether vancomycin (VAN) plus piperacillin-tazobactam (PTZ) could increase the risk of acute kidney injury (AKI) is still controversial in critically ill patients. The purpose of this study was to compare the risk of developing AKI and risk of developing AKI and treatment cost among this population receiving VAN/PTZ to a matched group receiving VAN/other antipseudomonal β-lactams. <bold>Methods</bold>: This multicenter, retrospective, matched study included 700 critically ill patients who received ≥48 hours of VAN/PTZ or VAN/other antipseudomonal β-lactams. The risk of developing AKI was compared between these two combination therapies using propensity-adjusted analysis. Furthermore, a pharmacoeconomic decision-analytic model was performed.<bold>Results</bold>: According to three AKI-defined criteria, VAN/PTZ was associated with significantly higher incidence of than VAN/other antipseudomonal β-lactams (all <italic>P</italic> &lt; 0.001). In multivariate analysis, regardless of any VAN/other antipseudomonal β-lactams, VAN/PTZ was an independent predictor for stage 2 or 3 AKI. In the empiric treatment, the incremental cost-effectiveness ratios per additional nephrotoxic episode of 1147.35$, 1845.11$, and 3989.95$ were found for VAN/PTZ relative to, vancomycin plus imipenem-cilastatin, vancomycin plus meropenem, and vancomycin plus cefoperazone-sulbactam, respectively. <bold>Conclusion</bold>: In critically ill patients, VAN/PTZ was associated with both higher AKI risk and treatment cost when considering AKI occurence compared to VAN/other antipseudomonal β-lactams.<bold>Trial registration</bold>: retrospectively registered, ClinicalTrials.gov number: NCT03776409.
BibTeX
@inproceedings{dong2021incidence,
  author = {Yalin Dong and Ying Zhang and Yan Wang and Jiangping Lian and Ruixia Yang and Lihui Long and Yin Wu and Yan Jianhua and Fei Shang and Kanghuai Zhang and Lirong Peng and Jianlin Huang and Dong Liu and Xialing Jiao and Linghong Huang and Kangkang Yan and Xiaoe Li and Hefeng Zhang and Yaling Shi and Bao Sun and Wenli Hai and Xiaoting Li and Jianping Zhang and Yan Cai and Xiaonian Han and Wangwang Duan and Jin Zhang and Kai Jiang and Le Zhang and Minchun Chen and Yan-Sheng Kang},
  title = {{Incidence Evaluation of Acute Kidney Injury and Pharmacoeconomic Analysis Among Critically Ill Patients With Use of Antipseudomonal β-Lactams and Vancomycin}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-298013/v1},
}
Figure